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Focal and segmental glomerulosclerosis (FSGS) is one of
the most important causes of end-stage renal failure. The
bradykinin B1 receptor has been associated with tissue
inflammation and renal fibrosis. To test for a role of the
bradykinin B1 receptor in podocyte injury, we
pharmacologically modulated its activity at different time
points in an adriamycin-induced mouse model of FSGS.
Estimated albuminuria and urinary protein to creatinine
ratios correlated with podocytopathy. Adriamycin injection
led to loss of body weight, proteinuria, and upregulation
of B1 receptor mRNA. Early treatment with a B1 antagonist
reduced albuminuria and glomerulosclerosis, and inhibited
the adriamycin-induced downregulation of podocin, nephrin,
and a-actinin-4 expression. Moreover, delayed treatment
with antagonist also induced podocyte protection.
Conversely, a B1 agonist aggravated renal dysfunction and
even further suppressed the levels of podocyte-related
molecules. Thus, we propose that kinin has a crucial role in
the pathogenesis of FSGS operating through bradykinin
B1 receptor signaling.
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Focal and segmental glomerulosclerosis (FSGS) is one of the
most important causes of end-stage renal failure.1,2 FSGS is
characterized by areas of glomerular sclerosis associated with
tubular atrophy and interstitial fibrosis with commitment
of the podocytes that lead to proteinuria.3 Podocytes are
polarized cells that possess a cytoskeleton that modulates
their foot processes that adhere to the glomerular basement
membrane.4,5 The foot processes are linked laterally by
negative charge structures named slit diaphragms,5 that are
an important filtration barrier composed of many proteins
like nephrin (NPHS-1), NEPH-1, podocin (NPHS-2),
CD2AP, ZO-1, and a-actinin-4.4,6,7
Recently, some experimental data demonstrated a protec-
tive role of bradykinin blockade in acute and chronic kidney
injury models.8 Bradykinin signals through two G-protein-
coupled receptors, the B1 (B1RBK) and B2 (B2RBK)
receptors. B2RBK is constitutively expressed in most tissues
and mediates the majority of the physiological actions
of kinins. On the other hand, B1RBK is overexpressed in
inflammatory conditions.9,10 The absence or blockade of
B1RBK is generally protective in renal disease models.8,11–13
Nevertheless, the role of B1RBK in FSGS is still unclear. Here,
we hypothesize that B1RBK also plays an important role in
podocytopathy, which is a hallmark of FSGS. Blocking
B1RBK signaling could be a new strategy to halt the
progression of FSGS and prevent end-stage renal disease.
RESULTS
Bradykinin receptors are upregulated in an
adriamycin-induced FSGS model
FSGS was induced in BALB/c mice14,15 by a single
intravenous injection of adriamycin. The adriamycin-in-
duced nephropathy model is a model of FSGS that
mimics many features of human disease. The animals
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with adriamycin nephropathy lost weight (Supplementary
Figure S1A online). Serum creatinine was significantly higher
in adriamycin-treated animals at day 28 after injection
(Supplementary Figure S1B online). We analyzed the urinary
protein/creatinine ratio (Supplementary Figure S1C online),
estimated the amount of albuminuria (Supplementary Figure
S1D online), and quantified the glomerulosclerosis and
tubular degeneration at different time points (Supplementary
Figure S1E online). The adriamycin-treated animals showed a
progressive and significant augmentation in the amount of
proteinuria and albuminuria (Supplementary Figure S1C and
D online) up to day 14. These animals also presented a
progressive increase in glomerulosclerosis and tubular
damage (Supplementary Figure S1E online).
To study the participation of kinin receptors during
adriamycin nephropathy, we first evaluated the expression of
B1RBK and B2RBK mRNAs using real-time PCR (Figure 1).
Treatment with adriamycin induced the expression of B1RBK
at 24 h (Figure 1a), and this expression progressively
increased thereafter. The relative expression of B2RBK mRNA
increased progressively from day 7 until day 14, when its
expression stabilized (Figure 1b). The relative expression of
B2RBK mRNA increased progressively from day 7 until day
14 (Figure 1b). As previous studies13,16 have shown a possible
compensatory relationship between B1RBK and B2RBK,
characterized by higher B1RBK expression in B2-knockout
mice, we evaluated the ratio of B1RBK to B2RBK that was
significantly higher in the adriamycin-treated animals from
day 1 to day 10 after injection compared with other days
(Figure 1c).
Early treatment of animals with DALBK protects animals from
adriamycin-induced nephropathy
First, to address whether B1RBK is involved in the initiation
of podocytopathy, animals were treated with des-Arg9-
[Leu8]-bradykinin (DALBK) on days 1–3 after adriamycin
administration and killed on day 4.
DALBK-treated animals were fully protected from albu-
minuria (Figure 2a) and presented less prominent weight
loss (Supplementary Figure S2A online) and proteinuria
(Supplementary Figure S2B online).
The DALBK treatment augmented the expression of
NPHS-2 mRNA (Figure 2b); however, there was no difference
in the renal protein levels of this marker (Figure 2c). Another
podocyte marker for slit diaphragm selectivity, NPHS-1,
appeared to be restored by DALBK treatment (Supplemen-
tary Figure S2C online). On the other hand, the mRNA levels
of a-actinin-4 showed no difference (Supplementary Figure
S2D online); furthermore, mRNA levels of transforming
growth factor-b (TGF-b), plasminogen activator inhibitor-1
(PAI-1), and vimentin were upregulated in FSGS. The
DALBK treatment downregulated mRNA levels of PAI-1,
vimentin (Supplementary Figure S2E and F online), and
mRNA and protein levels of tumor necrosis factor-a (TNF-a;
Figure 2d and e).
We found no difference in TGF-b levels among the groups
(Figure 2f). To investigate the effect of early DALBK
treatment on podocyte cell structure, we analyzed the
glomerular structure by electron microscopy. We observed
that DALBK treatment protected against adriamycin-induced
podocyte foot process effacement (Figure 2g). The degrees of
glomerulosclerosis and tubular damage showed no differ-
ences, although the DALBK-treated groups presented no
mesangial hypercellularity observed in the adriamycin group
(Supplementary Figure S2G online).
Early blockade of B1RBK induced a sustained protection
against adriamycin-induced nephropathy
Here, we evaluated whether B1RBK blockade could lead to
long-term renoprotection. Animals were treated with DALBK
on days 1–3 and were followed for up to 28 days. Indeed,
animals treated with DALBK showed lower albuminuria
(Figure 3a), body weight loss, and proteinuria (Supplemen-
tary Figure S3A and B online).
The mRNA levels of NPHS-2, which was downregulated
with adriamycin, were restored to basal levels with the
DALBK treatment (Figure 3b). NPHS-2 protein (Figure 3c),
NPHS-1, and ACTN-4 (Supplementary Figure S3C and D
online) presented similar results.
The DALBK treatment diminished the adriamycin-in-
duced upregulation of mRNA and renal tissue levels of
TGF-b (Figure 3d and e) and PAI-1 and vimentin mRNA
(Supplementary Figure S3E and F online).
The mRNA expression of TNF-a was reduced with
DALBK treatment (Figure 3f), and renal a-smooth muscle
actin protein expression was less evident in DALBK-treated
animals (Figure 4). Furthermore, there was a redistribution
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Figure 1 |Bradykinin receptor mRNA expression kinetics
during adriamycin nephropathy. B1RBK mRNA expression starts
rapidly after adriamycin (ADM) injection (24 h) and increases
progressively until day 14 (a). B2R mRNA expression starts only
7 days after ADM injection and continues until day 28 (b). In (c),
the B1R/B2R ratio demonstrates that B1R is more highly expressed
than B2R in the first 10 days of the disease. B1R, bradykinin 1
receptor; B2R, bradykinin 2 receptor; HPRT, hypoxanthine
phosphoribosyltransferase 1. *Po0.05; n¼ 5 animals per group.
Bars¼mean and s.e.m.
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Figure 2 | Early treatment with the bradykinin 1 receptor (B1R) antagonist des-Arg9-[Leu8]-bradykinin (DALBK) protects mice from
adriamycin (ADM)-induced nephropathy. The administration of DALBK on days 1–3 after ADM injection protects mice from the disease
symptoms. On day 4 after injection, the ADMþDALBK-treated animals lost less albumin in the urine (a). DALBK treatment augments the
mRNA (b) and protein levels (c) of podocin. Serum protein (d) and mRNA levels of tumor necrosis factor-a (TNF-a; e) are downregulated in
the ADMþDALBK group. The treatment did not affect the levels of transforming growth factor-b (TGF-b; f). After DALBK treatment on
day 7, animals were protected from podocyte foot process effacement (arrows), as shown by electron microscopy (g). The pictures
were taken with an original magnification of  10,000. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPRT, hypoxanthine
phosphoribosyltransferase 1; NPHS-2, nephrosis 2, idiopathic, steroid-resistant (podocin). *Po0.05 vs control, #Po0.05 vs ADM. Bars¼mean
and s.e.m.
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Figure 3 |Bradykinin 1 receptor (B1R) antagonist des-Arg9-[Leu8]-bradykinin (DALBK) treatment promotes sustained protection of
mice from the progression of adriamycin (ADM)-induced nephropathy after 28 days. The administration of DALBK on days 1–3 after
ADM injection protects mice from albuminuria (a). The mRNA (b) and protein (c) levels of podocin, which were downregulated with ADM
injection, are at basal levels with DALBK treatment. The mRNA (d) and renal tissue (e) levels of transforming growth factor-b (TGF-b) were at
basal levels in the DALBK-treated group. The mRNA level of tumor necrosis factor-a (TNF-a; f) is downregulated in the ADMþDALBK-
treated group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPRT, hypoxanthine phosphoribosyltransferase 1; NPHS-2, nephrosis
2, idiopathic, steroid-resistant (podocin). *Po0.05 vs control, #Po0.05 vs ADM; n¼ 5 animals per group. Bars¼mean and s.e.m.
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of podocin and podoplanin (Figure 4) in the glomeruli. The
DALBK-treated animals showed no glomerulosclerosis and a
minimal tubular degeneration. Furthermore, the animals
showed no mesangial hypercellularity or tubular atrophy
(Supplementary Figure S3G–L online), and low levels of
serum urea (Supplementary Figure S4 online).
Delayed DALBK treatment reverses podocyte dysfunction
in adriamycin nephropathy
Next, we evaluated whether B1RBK blockade is able to reverse
FSGS. To analyze this question, animals were treated on days
4–6 after adriamycin injection and were killed at day 7.
Mice treated with DALBK lost significantly less
albuminuria (Figure 5a), and presented a lower body
weight loss (Supplementary Figure S5A online), proteinuria
(Supplementary Figure S5B online), and serum urea levels
(Supplementary Figure S4 online) compared with only
adriamycin-treated animals. Postponed treatment with
DALBK also restored the protein and mRNA levels of
podocin (Figure 5a–c) and mRNA level of nephrin (Supple-
mentary Figure S5C online), but no difference was found in
a-actinin-4 (Supplementary Figure S5D online).
The renal tissue active protein and mRNA concentrations
of TGF-b (Figure 5d and e), which were upregulated after
adriamycin treatment, were significantly reduced in the
DALBK-treated group. DALBK treatment also diminished
the expression of the PAI-1 and vimentin (Supplementary
Figure S5E and F online), and prevented the increase
in renal mRNA and serum protein levels of TNF-a
(Figure 5f and g).
The animals treated with DALBK showed no glomerulo-
sclerosis. This result differs from those animals treated with
only adriamycin (Supplementary Figure S5G–K online),
which on day 7 had a sclerosis index of 5%. We observed
lower degrees of tubular degeneration and mesangial
hypercellularity and no tubular atrophy in the DALBK-
treated group (Supplementary Figure S5G–K online).
Delayed blockade of B1RBK induces long-term protection
against adriamycin-induced nephropathy
We next evaluated whether delayed treatment with DALBK
could halt the progression of adriamycin nephropathy
by treating animals on days 4–6 after adriamycin injection
and followed them until day 28.
In contrast to the first delayed treatment, the health of
the animals improved with time, and on day 28 they showed
no signs of albuminuria (Figure 6a) and showed decreases in
proteinuria (Supplementary Figure S6A online) and serum
urea (Supplementary Figure S4 online).
Furthermore, the levels of podocyte and fibrotic-related
proteins were returned to basal levels with delayed DALBK
treatment (Supplementary Figure S6A–E online). Interest-
ingly, renal mRNA and protein levels of NPHS-2 were
restored to basal levels in the DALBK-treated group (Figure
6b and c). The same was observed for renal mRNA levels of
TGF-b and TNF-a (Figure 6d and e).
Control ADM ADM+DALBK
Podocin
Podoplanin
α-SMA
Figure 4 |Bradykinin 1 receptor (B1R) antagonist des-Arg9-[Leu8]-bradykinin (DALBK) treatment protects against proliferating cell
nuclear antigen (PCNA) deposition and also maintains the structure of podocyte-related proteins. The administration of DALBK
on days 1–3 after adriamycin (ADM) injection protects renal tissue from PCNA deposition (arrows) and also prevented the redistribution of
podocin (arrows) and podoplanin (arrows); n¼ 5 animals per group. The pictures were taken with an original magnification of  40.
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Renal histology analysis showed no signs of adriamycin
nephropathy (Supplementary Figure S6F–L online).
Effect of B1RBK antagonism on heme oxygenase-1
expression
We observed that neither early nor delayed treatment of the
animals with DALBK induced heme oxygenase-1 mRNA
expression; however, this molecule was upregulated in
adriamycin-treated mice (Supplementary Figure S7 online).
Treatment of animals with DABK aggravates
adriamycin-induced nephropathy
B1RBK can also be positively regulated using an agonist,
des-Arg9-bradykinin (DABK). The early activation of
B1RBK accelerated the progression of FSGS (Figure 7 and
Supplementary Figure S8 online). DABK-treated animals
exhibited augmented albuminuria compared with animals
subjected to only adriamycin treatment (Figure 7a). However,
total proteinuria and body weight were not significantly different
from this latter group (Supplementary Figure S8A and B online).
Despite the clinical signs, DABK administration signifi-
cantly diminished mRNA and protein expression of NPHS-2
(Figure 7b and c), and no differences were found in the
other molecules (Figure 7d–f and Supplementary Figure
S8C–E online). Furthermore, the B1RBK agonist significantly
augmented vimentin mRNA expression (Supplementary
Figure S8F online). Moreover, DABK treatment induced
tubular atrophy that was not observed in the other groups
(Supplementary Figure S8G and H online).
Effect of kinin B1 modulation on macrophage infiltration
induced by adriamycin-induced nephropathy
Macrophage infiltration was analyzed by flow cytometry and
by quantification of chemokine mRNAs associated with this
process 17–19 (Figure 8). By day 4 after adriamycin injection,
B1RBK agonist, DABK, markedly augmented the level
of macrophages in the kidney (Figure 8d and g). However,
at day 7, the group treated with the antagonist, DALBK,
had a diminished level of macrophages within the kidneys
induced by adriamycin injection (Figure 8e, f, and h).
Furthermore, we observed that adriamycin increased the
renal levels of MCP-1 (monocyte chemotactic protein-1),
at day 4 (Supplementary Figure S9A online) and levels of
MCP-1, MIP-1 (macrophage inflammatory protein 1) and
RANTES at day 7 (Supplementary Figure S9B, D, F, and H
online) after its injection, whereas DALBK diminished them.
Interestingly, DABK enhanced the expression of MCP-1 and
MIP-1 (Supplementary Figure S 9A and E online).
B1RBK modulates metalloproteinases MMP-9 and TIMP-1
Matrix metalloproteinase-9 (MMP-9) is a molecule asso-
ciated with extracellular matrix degradation and decrease
of fibrosis.20 Here, we observed that DALBK augmented
MMP-9 level (Supplementary Figure S10A and C online);
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Figure 5 |Delayed treatment with the bradykinin 1 receptor (B1R) antagonist des-Arg9-[Leu8]-bradykinin (DALBK) reverses the
progression of adriamycin (ADM)-induced nephropathy. The administration of DALBK on days 4–6 after ADM injection attenuates the
progression of ADM-induced nephropathy on day 7. The ADMþDALBK-treated animals showed less albuminuria (a) than animals treated with
only ADM. DALBK administration augments the mRNA (b) and prevents the downregulation of protein levels of podocin (c), which were
downregulated by ADM injection. The DALBKþADM-treated group shows lower renal transforming growth factor-b (TGF-b) mRNA (d) and
protein levels by enzyme-linked immunosorbent assay (ELISA; e). The mRNA and serum levels of tumor necrosis factor-a (TNF-a) are also
downregulated after DALBK treatment (f, g). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPRT, hypoxanthine phosphoribosyltransferase
1; NPHS-2, nephrosis 2, idiopathic, steroid-resistant (podocin). *Po0.05 vs control, #Po0.05 vs ADM. Bars¼mean and s.e.m.
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Figure 7 |Bradykinin 1 receptor (B1R) agonist des-Arg9-bradykinin (DABK) treatment aggravates the symptoms of adriamycin
(ADM)-induced nephropathy. DABK administration on days 1–3 after ADM injection induced more albuminuria (a) than ADM treatment
alone. The administration of DABK diminishes the mRNA levels of podocin (b). A significant downregulation of podocin, as analyzed by
western blot, is seen in the ADMþDABK group (c). No differences were found when we analyzed transforming growth factor-b (TGFb)
mRNA (d). There was no difference between the groups in mRNA and serum protein levels of tumor necrosis factor-a (TNF-a; e, f). GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; HPRT, hypoxanthine phosphoribosyltransferase 1; NPHS-2, nephrosis 2, idiopathic, steroid-
resistant (podocin). *Po0.05 vs control, #Po0.05 vs ADM. Bars¼mean and s.e.m.
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Figure 6 | The bradykinin 1 receptor (B1R) antagonist des-Arg9-[Leu8]-bradykinin (DALBK) reverses the progression of adriamycin
(ADM)-induced nephropathy after 28 days of study. The administration of DALBK on days 4–6 after ADM injection diminished the levels
of albuminuria (a) and also prevented increases in the mRNA (b) and protein levels (c) of podocin. The mRNA level of the fibrotic marker
transforming growth factor-b (TGF-b; d) were at basal levels in the ADMþDALBK group, and the level of tumor necrosis factor-a (TNF-a; e)
showed the same pattern; n¼ 5 animals per group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPRT, hypoxanthine
phosphoribosyltransferase 1; NPHS-2, nephrosis 2, idiopathic, steroid-resistant (podocin). *Po0.05 vs control, #Po0.05 vs ADM. Bars¼mean
and s.e.m.
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on the other hand, adriamycin induced TIMP-1 (tissue
inhibitor of matrix metalloprotease-1) expression, a MMP-9
inhibitor, whereas DALBK diminished it (Supplementary
Figure S10B and D online). DABK treatment did not alter the
levels of these proteins (Supplementary Figure S10A and
B online).
Effect of B1RBK modulators on cell proliferation
Cell proliferation is closely related to tubular and glomerular
injury.21 We observed strong nuclear staining for proliferating
cell nuclear antigen in the tubular and glomerular area of the
kidneys in adriamycin-induced nephropathy (Figure 9). Ani-
mals treated with DALBK presented less prominent staining
(Figure 9c and f). In contrast, DABK treatment augmented the
number of proliferating cell nuclear antigen-positive cells
(Figure 9d).
Effect of B1RBK modulators on interleukin-1b expression
We observed that delayed treatment with B1RBK antagonist,
DALBK, decreased interleukin-1b expression, compared
with adriamycin-induced nephropathy group at day 7.
In contrast, on day 4, there was no difference in inter-
leukin-1b level among all groups (Supplementary Figure S11
online).
DISCUSSION
Because B1RBK is involved in many inflammatory and
fibrotic disorders,8,12,13,17,22–26 we hypothesized that its
blockade could have a protective role in adriamycin-induced
FSGS. Several studies have shown that the blockade and
deletion of this receptor are associated with less inflamma-
tion and fibrosis,23,24,27,28 but no data were reported in FSGS.
The upregulation of B1RBK has previously been associated
with glomerular diseases.29
To assess the role of B1RBK in FSGS, we observed that this
receptor is quickly upregulated during the disease, from days 1
to 28, as observed in other studies,13 which in turn helped us to
determine a strategy to modulate this receptor. Initially, we
evaluate whether the early blockade of B1RBK influence the
development of FSGS. Because FSGS is a podocyte-related
disease,6,17,29,30 we analyzed the mRNA and protein expression
of podocyte markers, such as nephrin, podocin, and a-actinin-
4.31,32 Indeed, animals treated with the antagonist were
protected, with decreased levels of proteinuria and podocyte
damage. Conversely, when we used an agonist for B1RBK, we
observed the opposite result, corroborating the idea that the
bradykinin acting through B1RBK is deleterious to FSGS
progression, as observed in other fibrotic pathologies.8,10–13,23,33
In a delayed treatment with DALBK, we observed a
progressive augmentation in renal fibrosis, which was
associated with an increase in mRNA and protein expression
of fibrosis-related proteins, such as TGF-b, PAI-1, and
vimentin, and with a downregulation of podocyte-specific
proteins. We investigated the long-term outcomes of early
and delayed B1RBK blockade. We quantified renal mRNA
and/or protein levels of TGF-b, PAI-1, and vimentin.13,34–36
TGF-b has been associated with many fibrotic diseases,13,34
and together with upregulation of TNF-a, is implicated in
the progression of proteinuria in FSGS, especially because of
its role in the downregulation of nephrin.37 Interestingly, the
treatment with DALBK prevented the upregulation of these
molecules. TGF-b is also associated with the downregulation
of MMP-9 and, consequently, augmentation of extracellular
matrix proteins, contributing to fibrosis.18 Here, TIMP-1, an
inhibitor of MMP-9, was upregulated in adriamycin-treated
animals, whereas DALBK diminished its expression.
Shin et al.38 showed that adriamycin accumulates in the
glomerulus, and its delayed clearance causes a continuous
noxious insult associated with reactive oxygen species
release that consequently leads to podocyte damage.39–41
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Figure 8 | The bradykinin 1 receptor (B1R) antagonist
Des-Arg9-[Leu8]-bradykinin (DALBK) diminished the level of
macrophages in renal tissue, and the B1 receptor agonist
des-Arg9-bradykinin (DABK) augmented the macrophage
level. (a) Negative control; (b) saline-treated animals; (c) kidney
sample collected 4 days after adriamycin injection; (d) kidney
samples from mice treated with adriamycin and on days 1–3 with
DABK; (e) kidney samples collected after 7 days of adriamycin
treatment; (f) kidney samples collected from animals injected with
adriamycin and with DALBK on days 4–6 after adriamycin
injection; (g, h) index of macrophage infiltration. *Po0.05 vs
control, #Po0.05 vs ADM. Bars¼mean and s.e.m. SSCA, side or
orthogonal scatter: measures cell complexity or granularity.
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Corroborating this finding, we observed upregulation of
heme oxygenase-1 in adriamycin-treated mice; however, this
marker was not upregulated by DALBK in our work. Another
factor associated with DALBK-induced protection was the
decreased glomerular and tubular cell proliferation, as
assayed by proliferating cell nuclear antigen staining.21
A possible role of macrophages in FSGS was verified in
other studies.42 Here, we observed that DALBK-treated
animals presented macrophage infiltration levels similar to
control, which could be associated with the downregulation
of macrophage chemokines as seen by Klein et al.43
The redistribution of slit diaphragm proteins is a common
feature of glomerular diseases.32,44–46 In our model, we
observed that adriamycin-induced nephropathy caused a
similar redistribution of podocin and podoplanin, as
previously observed.45 All these alterations observed under
adriamycin treatment were prevented by DALBK.
Our study is the first to evaluate the role of B1RBK in
FSGS. We observed that B1RBK has an important role in
FSGS progression and that its blockage is important for the
prevention and effective reversion of adriamycin-induced
FSGS. Therefore, our findings should provide new and
valuable perspective on FSGS management.
MATERIALS AND METHODS
Methods
Animals. Isogenic male BALB/c mice, age 8–12 weeks (23–28 g),
were obtained from the Animal Care Facility at the Federal
University of Sa˜o Paulo (UNIFESP). All animals were housed in
individual standard cages and had free access to water and food. All
procedures were previously reviewed and approved by the internal
ethical committee of the Institution.
Experimental model of FSGS induced by adriamycin. FSGS
was induced in mice by a single tail vein injection of 10mg/kg
adriamycin (doxorubicin hydrochloride; Pfizer, New York, NY),14,17
whereas an equal volume of saline was given to control mice.
Modulation of B1RBK. B1RBK was modulated using three
different protocols. First, we treated animals with intraperitoneal
injection of 10mg/kg of the B1RBK antagonist DALBK (Sigma,
St Louis, MO)22 on days 1–3 after adriamycin injection. The animals
were killed on days 4 or 7. In the second protocol (delayed treatment),
animals received DALBK on days 4–6 after adriamycin injection13 and
were killed on days 7 and 28. In the third protocol, we treated animals
on days 1–3 after adriamycin injection, and then the animals were
killed on day 28. Finally, some animals were also treated with a B1RBK
agonist (DABK; Sigma). Animals received an intravenous injection of
1.5mg/kg of DABK on days 1–3 after adriamycin injection. Mice were
killed on day 4 for further analysis.13
Renal function analyses
On days 1, 4, 7, 10, 14, 21, and 28 after adriamycin injection, urinary
and blood samples were collected. Serum creatinine and urea, the
urinary protein/creatinine ratio, and albuminuria were used to
estimate renal and podocyte functions. At the time of killing, blood
and urine were collected. All samples were analyzed using Labtest
Diagnosis (Belo Horizonte, State of Minas Gerais, Brazil) for creatinine
measurements and Sensiprot for protein measurements. To estimate
the urinary albumin concentration, 10ml of urine (1mg/ml), corrected
for urinary creatinine level, was separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and stained with Coomas-
sie. The density of the bands was analyzed using the software
GeneSnap and Gene Tools (Syngene, Cambridge, UK).
Expression of slit diaphragm-related genes
Kidney samples were frozen in liquid nitrogen. Total RNA
was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA).
First-strand cDNAs were synthesized using Moloney murine
leukemia virus reverse transcriptase (Promega, Madison, WI).
Real-time PCR was performed using the TaqMan primers and
probes for TIMP-1 (Mm 00441818), MMP-9 (Mm01240560),
PCNA deposition
Figure 9 | Early treatment with bradykinin 1 receptor (B1R) antagonist des-Arg9-[Leu8]-bradykinin (DALBK) diminished the
proliferating cell nuclear antigen (PCNA) deposition induced by adriamycin (ADM), whereas the B1 receptor agonist des-Arg9-
bradykinin (DABK) did not. Both were analyzed on days 4 and 7 after its injection. (a) Control; (b) ADM at day 4; (c) ADMþDALBK (DALBK
treatment at days þ 1, þ 2, and þ 3) at day 4; (d) ADMþDABK at day 4 (DABK treatment at days þ 1, þ 2, and þ 3); (e) ADM at day 7; and
(f) ADMþDALBK (DALBK treatment at days þ 4, þ 5, and þ 6) at day 7. All photographs were taken with an original magnification of  40.
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NPHS-1 (Mm004497831_g1), vimentin (Mm 00801666-g1), TNF
(Mm0136932), and PAI-1 (Mm 009312) (Applied Biosystems,
Foster City, CA). For the analyses of B1RBK, B2RBK, TGF-b,
NPHS-2, ACTN-4, interleukin-1b, and MCP-1 expression, real-time
PCR was performed using a SYBRGreen assay (Applied Biosystems;
Table 1).
The cycling conditions of both TaqMan and SYBRGreen primers
were as follows: 10min at 95 1C, followed by 45 cycles of 30 s at
95 1C, 30 s at 60 1C, and 30 s at 72 1C. The relative quantification of
mRNA levels was performed as described in detail in User Bulletin 2
(PerkinElmer, Applied Biosystems, Branchburg, NJ, 1997). Briefly,
the target gene amount was normalized to the endogenous reference
(hypoxanthine phosphoribosyltransferase 1 (HPRT); SYBRGreen)
and then related to a calibrator (sample with the lowest expression,
namely the controls) using the formula 2DDCt. Hence, all data
were expressed as an N-fold difference related to the expression of
matched controls. Analyses were performed with the Sequence
Detection Software 1.9 (Applied Biosystems).
Immunohistochemistry
The localization of a-smooth muscle actin (diluted 1:600; DAKO,
Glostrup, Denmark) and proliferating cell nuclear antigen (diluted
1:300; DAKO) was performed according to the manufacturer’s
instructions for the staining procedures.
The localization of nephrin (NPHS-2 antibody diluted to
10 mg/ml; Abcam, Cambridge, UK) and podoplanin diluted in a
1:100 concentration (Biolegends, San Diego, CA) was detected in
frozen sections of the kidney. The sections were fixed and performed
according with the manufactures’ instructions.
Determination of TGFb-1 protein by enzyme-linked
immunosorbent assay
Total renal TGFb-1 protein was measured using a TGFb-1 Emax
immunoassay system (Promega), according to the manufacturer’s
instructions. The results are presented as TGFb-1 pg/mg of total
protein measured using the Bradford assay (Bio-Rad, Hercules, CA).
Western blotting for podocin
Briefly, 100 mg of total protein from renal tissue was collected and
then diluted in sample buffer (Bio-Rad), containing 20mg/ml of
2-b-mercaptoethanol (Sigma). NPHS-2 and GAPDH antibodies
were purchased from Abcam, and western blot was done according
to the manufacturer’s instructions.
TNF-a serum measurement
A Bio-Plex mouse cytokine assay kit (Bio-Rad) was used to test
samples for the presence of TNF-a. The assay was read on the
Bio-Plex suspension array system, and the data were analyzed using
Bio-Plex Manager software version 4.0. Standard curves ranged from
32,000 to 1.95 pg/ml.
Renal histology analysis
Kidney samples were fixed in 10% neutral formalin. Paraffin
sections (3mm in thickness) were cut and stained with hematoxylin
and eosin. The sections were analyzed in a trinocular optical
microscope (Olympus Corporation, Tokyo, Japan). Photographs
were taken through the digital camera coupled with the microscope,
and the images were captured with the software Pinnacle Studio
Plus (Pinnacle Systems, Bucks, UK). All sections were evaluated at
 40 magnification.
Glomerulosclerosis was evaluated as described by Mu et al.47
The extent of glomerulosclerosis and glomerular collapse was
evaluated in each kidney by consecutive examination under light
microscopy. Tubulointerstitial injury was defined as tubular dilation
and/or atrophy or as interstitial fibrosis.48
Tubular injuries were examined in at least 20 areas using the
following scoring system: 0¼ changes in o10% of the cortex,
1þ ¼ changes in up to 25% of the cortex; 2þ ¼ changes in up to
50% of the cortex; and 3þ ¼ changes in450% of the cortex sections.
Flow cytometry analysis
Animals were killed, and the kidneys were collected for flow
cytometry analysis, following the standard manufacturer’s proceed-
ing and the compensation process was made according to the
‘fluorescence minus one’ method.49
We analyzed the renal macrophage population by multicolor
flow cytometry. The monoclonal antibody used was F4/80 PerCP
(BD Biosciences, Franklin Lakes, NJ). Samples were acquired on a
FACSCanto, using FACSDIVA software (BD Biosciences) and then
were analyzed with FLOWJO software (Tree Star, San Carlo, CA).
Fluorescence voltages were determined using matched unstained
cells. Compensation was carried out using cells (BD Biosciences)
single-stained with CD3 PerCP, CD4 FITC, CD8 APC-CY7, CD4
PE-CY7, CD3 PE, or CD3 APC. Samples were acquired up to at least
200,000 events in a live mononuclear gate.
Electron microscopy analysis
Samples for electron microscopy were processed according to
standard methods as described by Ertmer et al.50 The glomerular
and podocyte foot processes structures were analyzed.
Statistical analysis
All data are presented as the mean±s.e.m. Different results among
groups were compared using analysis of variance. Significance was
Table 1 | Base pair sequence of primers (probes) used in real-time PCR assays
Gene Sense Antisense
HPRT 50-CTCATGGACTGATTATGGACAGGAC-30 50-GCAGGTCAGCAAAGAACTTATAGCC-30
B1R 50-CCATAGCAGAAATCTACCTGGCTAAC-30 50-GCCAGTTGAAACGGTTCC-30
B2R 50-ATGTTCAACGTCACCACACAAGTC-30 50-TGGATGGCATTGAGCCAAC-30
TGF-b 50-AACTATTGCTTCAGCTTCACAGAGA 30 50-AGTTGGATGGTAGCCCTTG-30
ACTN-4 50-CGCTGAGAGCAATCACATCA-30 50-AGTGCAATGGTCCCTCTTTGG-30
NPHS-2 50-ATGCTCCCTTGTGCTCTGTTG-30 50-TTTGCCTTTGCCATTTGACA-30
IL-1-b 50-CCTAAAGTATGGGCTGCACTGTTT-30 50-TAGAGATTGAGCTGTCTGCTCATTC-30
MCP-1 50-AAGAGAATCACCAGCAGCAGGT-30 50-TTCTGGACCCATTCCTTATTGG-30
Abbreviations: ACTN-4, actinin, a-4; B1R, bradykinin 1 receptor; B2R, bradykinin 2 receptor; HPRT, hypoxanthine phosphoribosyltransferase 1; IL-1-b, interleukin 1b; MCP-1,
monocyte chemotactic protein-1; NPHS-2, nephrosis 2, idiopathic, steroid-resistant (podocin); TGF-b, transforming growth factor-b.
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established as Po0.05. All statistical analyses were performed using
GraphPad PRISM (GraphPad, La Jolla, CA).
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Figure S2. Early treatment with the B1R antagonist des-Arg9-[Leu8]-
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reverses the upregulation of inflammatory and fibrotic markers and
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nephropathy.
Figure S7. Heme oxygenase kinetics in adriamycin-induced
nephropathy.
Figure S8. B1R agonist des-Arg9-bradykinin (DABK) treatment
aggravates the symptoms of adriamycin-induced nephropathy.
Figure S9. Treatment with B1 receptor modulators DALBK (at days 4,
5 and 6 after adriamycin injection) and DABK (at days 1, 2 and 3 after
adriamycin injection) alters the mRNA and renal tissue levels of
chemokines associated with macrophage infiltration.
Figure S10. Early treatment with B1 receptor modulators DALBK and
DABK alters the mRNA levels of matrix-associated proteins, which
were (A-B) analyzed 4 days after adriamycin injection and (C-D) 7 days
after adriamycin injection.
Figure S11. Treatment with B1 receptor modulators DALBK (at days
4, 5 and 6 after adriamycin injection) and DABK (at days 1, 2 and 3
after adriamycin injection) alters the renal mRNA and protein levels of
IL-1b (A-C) analyzed 4 days after adriamycin injection and (B-D) 7 days
after adriamycin injection.
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